Should NPDR patients be treated with anti-VEGF agents?
Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Dr Jennifer Sun, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials
